Part 3: Risk-based Quality Management Video (RBQM) Series
ICH Q9 (1) focuses on Quality Risk Management. Revisions may influence how we apply and perform risk management in clinical trials. In part three of our RBQM video series, Amy Kissam-Sands and Tim Audin, Senior Director, Global Biometrics Group Lead talk with Taren Grom, Editor, PharmaVOICE about the specific areas they expect ICH Q9 (1) to focus on.
Related Insights
Article
Decentralized trial tools and technologies are here to stay: A regulatory perspective
Jul 23, 2021
Video
Part 2: Risk-based Quality Management Video (RBQM) Series
Nov 11, 2021
Video
How to transition existing trials under EU-CTR
Feb 1, 2023
Webinar
Accelerating delivery of radiopharmaceutical trials
Oct 3, 2025
Report
New Medicines, Novel Insights: Advancing rare disease drug development
May 22, 2023
Report
New Medicines, Novel Insights: Accelerating development of cell and gene therapies
May 22, 2023
Article
Australia: The Regulatory and Reimbursement Environment
Aug 28, 2023
Article
How a joined-up development strategy pays off for early-stage biotechs
May 19, 2021
Article
Part 1 - Preparing for a Risk-Based Future: What ICH Revisions Mean for Clinical Trial Design and Conduct
Sep 14, 2021
Blog
Optimize your post-approval CMC change management in China with the ICH Q12 tool
Nov 24, 2025
Whitepaper
Scientific Validity Reports: a mandatory requirement for In Vitro Diagnostic Regulation (IVDR)
Sep 19, 2023
Article
Australia: Infrastructure and Innovations for Clinical Trials
Aug 28, 2023
Related Insights
Article
Decentralized trial tools and technologies are here to stay: A regulatory perspective
Jul 23, 2021
Video
Part 2: Risk-based Quality Management Video (RBQM) Series
Nov 11, 2021
Video
How to transition existing trials under EU-CTR
Feb 1, 2023
Webinar
Accelerating delivery of radiopharmaceutical trials
Oct 3, 2025
Report
New Medicines, Novel Insights: Advancing rare disease drug development
May 22, 2023
Report
New Medicines, Novel Insights: Accelerating development of cell and gene therapies
May 22, 2023
Article
Australia: The Regulatory and Reimbursement Environment
Aug 28, 2023
Article
How a joined-up development strategy pays off for early-stage biotechs
May 19, 2021
Article
Part 1 - Preparing for a Risk-Based Future: What ICH Revisions Mean for Clinical Trial Design and Conduct
Sep 14, 2021
Blog
Optimize your post-approval CMC change management in China with the ICH Q12 tool
Nov 24, 2025
Whitepaper
Scientific Validity Reports: a mandatory requirement for In Vitro Diagnostic Regulation (IVDR)
Sep 19, 2023
Article
Australia: Infrastructure and Innovations for Clinical Trials
Aug 28, 2023